Last --
Change Today 0.00 / 0.00%
Volume 0.0
1099 On Other Exchanges
1099 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sinopharm group co-h (1099) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SINOPHARM GROUP CO-H (1099)

Related News

No related news articles were found.

sinopharm group co-h (1099) Related Businessweek News

No Related Businessweek News Found

sinopharm group co-h (1099) Details

Sinopharm Group Co. Ltd., together with its subsidiaries, distributes pharmaceutical and healthcare products in the People’s Republic of China. The company operates in three segments: Pharmaceutical Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, customers, and other suppliers. This segment distributes prescription drugs and over-the-counter medicines from manufacturers and suppliers to hospitals, other medical institutions, retail drug stores, and other customers. As of December 31, 2013, it operated 51 distribution centers covering 31 provinces, municipalities, and autonomous regions in China. The Retail Pharmacy segment operates or franchises a network of retail drug stores. As of December 31, 2013, this segment had 1,917 retail pharmacies, which included 1,632 retail pharmacies operated by company and 285 operated by franchisees. The Other Business segment produces and sells pharmaceutical products, chemical reagents, and laboratory supplies. The company also distributes medical equipment, building decoration, communication, and clothing products, as well as chemical reagents; imports and exports goods and technology; and provides business consulting, pharmaceutical logistics, and import agency services. In addition, it is involved in the property rental, planting, property management, and asset management activities; provision of health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services; and sale of commodities. The company is headquartered in Shanghai, the People’s Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

45,415 Employees
Last Reported Date: 04/9/14

sinopharm group co-h (1099) Top Compensated Officers

President, Executive Director and Member of S...
Total Annual Compensation: CNY1.8M
Head of Auditing Department and Supervisor
Total Annual Compensation: CNY887.0K
Chief Supervisor
Total Annual Compensation: --
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

sinopharm group co-h (1099) Key Developments

Hutchison China MediTech Limited and Sinopharm Group Co. Ltd. Receives Regulatory Approval for the Establishment of New Joint Venture

Hutchison China MediTech Limited and Sinopharm Group Co. Ltd. have received regulatory approval for the establishment of their new joint venture, Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (formerly known as Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co. Ltd.).  Hutchison Sinopharm, which formally commences operations on April 25, 2014, is 51% held by Chi-Med and will be consolidated as a Chi-Med subsidiary and reported under its China Healthcare Division.

Sinopharm Group Co. Ltd. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2013

Sinopharm Group Co. Ltd. reported audited consolidated earnings results for the year ended December 31, 2013. For the year, the company reported revenue of RMB 166,866.146 million compared to RMB 136,501.660 million a year ago. Revenue increased primarily due to the increase in revenue from each of the Group's pharmaceutical distribution, retail pharmacy and other business segments. Operating profit was RMB 6,101.920 million compared to RMB 4,868.904 million a year ago. Profit before income tax was RMB 4,620.505 million compared to RMB 4,022.191 million a year ago. Profit for the year attributable to shareholders of the company was RMB 2,250.002 million or RMB 0.89 per basic and diluted share, compared to RMB 1,979.381 million or RMB 0.82 per basic and diluted share, a year ago. For the year 2013, total capital expenditure of the group amounted to RMB 2,013.17 million, which was primarily used for the expansion and development of distribution channels, and the enhancement of logistic delivery network and the level of informatization, so to increase the Group's market share and improve delivery efficiency. Net cash generated from operating activities was RMB 4,941.29 million compared to RMB 3,855.84 million a year ago.

Sinopharm Group Co. Ltd. Proposes Final Dividend for the Year Ended December 31, 2013

Sinopharm Group Co. Ltd. announced that dividend relevant resolution has been passed at a meeting of the board held on March 21, 2014 to propose to distribute a final dividend of RMB 0.26 per share (inclusive of tax) for the year ended December 31, 2013, totaling approximately RMB 667,756,000. The proposal in relation to the profit distribution will be submitted to the 2013 annual general meeting for shareholders' consideration and approval. The company will separately publish the relevant arrangements in respect of the distribution of the Final Dividend including the record date and the book closure period when the date of the 2013 annual general meeting of the company is fixed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1099:HK $20.55 HKD +0.25

1099 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chongqing Tong Jun Ge Co Ltd CNY8.91 CNY -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation 1099 Industry Range
Price/Earnings 18.1x
Price/Sales 0.3x
Price/Book 1.9x
Price/Cash Flow 18.4x
TEV/Sales NM Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINOPHARM GROUP CO-H, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at